Stem cell research introduction paper

On 23 January 2009, the US Food and Drug Administration gave clearance to Geron Corporation for the initiation of the first clinical trial of an embryonic stem-cell-based therapy on humans. The trial aimed evaluate the drug GRNOPC1, embryonic stem cell -derived oligodendrocyte progenitor cells, on patients with acute spinal cord injury . The trial was discontinued in November 2011 so that the company could focus on therapies in the "current environment of capital scarcity and uncertain economic conditions". [62] In 2013 biotechnology and regenerative medicine company BioTime ( AMEX :  BTX ) acquired Geron's stem cell assets in a stock transaction, with the aim of restarting the clinical trial. [63]

Stem cell research introduction paper

stem cell research introduction paper

Media:

stem cell research introduction paperstem cell research introduction paperstem cell research introduction paperstem cell research introduction paper